Be sure to check our sister interview main ratings news website

N4 Pharma Nuvec showing fantastic results (Interview)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss its operations update. Nigel explains what is involved in the Material Transfer Agreements that have been announced, whether these are exclusive, how the work done under the MTA and subsequent relationships may negate the need for the Company to do its own proof of concept work and what else investors can expect over the coming months.

N4 Pharma, are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    N4 Pharma

    More articles like this

    N4 Pharma

    N4 Pharma Q&A: Good, strong, steady progress (LON:N4P)

    27th May 2021

    N4 Pharma’s Nigel Theobald discusses the Material Transfer Agreements, collaborating with more partners, the in vivo studies, how the work done under the MTA may negate the need for the Company to do its own proof of concept work and what investors can expect in the coming months in this exclusive interview with DirectorsTalk.

    N4 Pharma

    N4 Pharma Q&A: A pivotal time for the company (LON:N4P)

    26th February 2021

    N4 Pharma’s Nigel Theobald discusses final results, updates on the three work streams, the European patent for Nuvec & what this means for the company and what investors can expect in the near future in this exclusive interview with DirectorsTalk.

    N4 Pharma

    N4 Pharma AGM to be held at 10.00am on 24 March 2021

    25th February 2021

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that the Company’s audited accounts for the year ended 31 December 2020, together with the

    DirectorsTalk

    N4 Pharma raises £2 million through placing

    9th December 2020

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £2 million (before expenses) through a placing of 25,000,000 new ordinary

    DirectorsTalk

    N4 Pharma update on Nanomerics research collaboration

    3rd December 2020

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided the following update on its ongoing research collaboration agreement with Nanomerics Limited. As announced on

    DirectorsTalk

    N4 Pharma Q&A: Confirming Nuvec’s versatility (LON:N4P)

    12th November 2020

    N4 Pharma’s Nigel Theobald discusses their latest operational update, the importance of demonstrating formulation, key milestones for the COVID-19 proof of concept programme, whyan orally administered vaccine has greater challenges than a subcutaneous injection and what news flow investors can expect from the company for the rest of the year in this exclusive interview with DirectorsTalk.

    DirectorsTalk

    N4 Pharma make significant strides with optimisation work

    5th November 2020

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided the following update on its ongoing work programmes. Optimisation The optimisation programme is investigating different formulations

    © 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.